Adverse reactions to TNF-α inhibitors in rheumatoid arthritis
- 1 February 2002
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 359 (9306) , 540-541
- https://doi.org/10.1016/s0140-6736(02)07718-8
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)Annals of the Rheumatic Diseases, 2001
- Infliximab-induced aseptic meningitisThe Lancet, 2001
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological CompoundsAnnals of the Rheumatic Diseases, 2000
- Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatmentAnnals of the Rheumatic Diseases, 1999
- Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2Neurology, 1996